Financial Performance - Net sales increased by 71.5% to $353.8 million for the year ended December 31, 2022, from $206.3 million in 2021, driven by a 116.0% increase in sales to the Medical market and an organic sales increase of approximately 24.0%[95][98]. - Gross margin improved to 25.5% for the year ended December 31, 2022, up from 24.8% in 2021, despite a 5.5% increase in material and labor costs[95][99]. - Operating income and net income for the year ended December 31, 2022, increased by 161.1% and 163.1%, respectively, despite challenges such as raw material and labor shortages[95]. Expenses and Costs - Selling, General, and Administrative Expenses (SG&A) rose approximately 55.3% to $45.8 million for the year ended December 31, 2022, but decreased as a percentage of sales to 12.9% from 14.3% in 2021[100]. - The Company incurred approximately $1.0 million in acquisition-related costs for the year ended December 31, 2022[102]. - The fair value of contingent consideration liabilities recognized at December 31, 2022, totaled approximately $14.6 million, with an expense of approximately $9.8 million recorded for the year[103]. - Net interest expense increased to approximately $2.8 million for the year ended December 31, 2022, primarily due to interest on funds drawn for acquisitions[106]. Cash Flow and Investments - Net cash provided by operations for the year ended December 31, 2022, was approximately $17.7 million, driven by net income of approximately $41.8 million[118]. - Net cash provided by investing activities was approximately $1.3 million, primarily from the sale of Molded Fiber and the Georgetown manufacturing facility[120]. - Net cash used for financing activities was approximately $25.9 million, primarily due to payments on the revolving line of credit of approximately $60 million and principal payments of long-term debt of approximately $4 million[121]. - The Company generated cash of approximately $17.7 million from operations during the year ended December 31, 2022, but future cash generation cannot be guaranteed[131]. Debt and Financing - As of December 31, 2022, the Company had approximately $55 million in borrowings outstanding under the Second Amended and Restated Credit Agreement, with an applicable interest rate of approximately 5.2%[125]. - The Second Amended and Restated Credit Agreement matures on December 21, 2026, and includes a secured term loan of $40 million and a revolving credit facility of up to $90 million[123]. - Future maturities of long-term debt total approximately $55 million, with $4 million due in 2023 and $24 million due in 2026[127]. - The Company uses interest-rate-related derivative instruments to manage exposure to changes in interest rates on variable-rate debt instruments[128]. - The Company is subject to a minimum fixed-charge coverage financial covenant and a maximum total funded debt to EBITDA financial covenant under the Second Amended and Restated Credit Agreement[124]. Future Plans - The Company plans to continue adding capacity to enhance operating efficiencies in its manufacturing plants throughout fiscal 2023[132]. - The Company anticipates that future business expansion will be financed through existing resources, cash flow from operations, and the revolving credit facility[133]. - At December 31, 2022, the Company had approximately $9.4 million available for future repurchases of its common stock under the stock repurchase program[134]. Asset Sales - The Company sold Molded Fiber Technology for approximately $31.5 million, resulting in a net gain of approximately $15.7 million recorded in 2022[104].

Sales Performance - Sales for the nine-month period ended September 30, 2022 increased 75.1% to $262.6 million from $150.0 million in the same period last year, driven by acquisitions and an organic sales increase of approximately 16.5%[97] - Sales for the three-month period ended September 30, 2022 increased approximately 91.2% to $97.0 million from $50.7 million for the same period in 2021, primarily due to a 152.0% increase in sales to customers in the Medical market[98] Financial Metrics - Gross margin for the three-month period ended September 30, 2022 increased to 26.3% from 23.7% for the same period in 2021, attributed to organic sales growth and decreased overhead costs[100] - Net interest expense for the nine-month period ended September 30, 2022 was approximately $1.9 million, significantly higher than $11 thousand in the same period of 2021, due to interest on funds drawn for acquisitions[110] - The effective tax rate for the nine-month period ended September 30, 2022 was approximately 22.4%, a decrease from 23.6% in the same period of 2021, primarily due to lower statutory rates on foreign taxable income[113] Expenses and Costs - Selling, general, and administrative expenses (SG&A) increased approximately 73.7% to $11.8 million for the three-month period ended September 30, 2022, primarily due to additional SG&A from recent acquisitions[102] - The Company incurred approximately $1.0 million in acquisition-related costs for the nine-month period ended September 30, 2022, primarily for legal and valuation services[104] - The fair value of contingent consideration payments for the DAS Medical and Contech Medical acquisitions totaled approximately $19.1 million as of September 30, 2022, with an expense of approximately $9.3 million recognized for the nine-month period[105] Cash Flow and Financing - Net cash used for operating activities for the nine-month period ended September 30, 2022 was approximately $144 thousand, with net income generated of approximately $33.3 million[115] - Net cash provided by investing activities during the same period was approximately $4.3 million, primarily from the sale of Molded Fiber and the Georgetown manufacturing facility[117] - Net cash used for financing activities was approximately $5.2 million, mainly due to payments on the revolving line of credit of approximately $45 million[118] - As of September 30, 2022, the Company had approximately $71 million in borrowings outstanding under the Second Amended and Restated Credit Agreement[122] - The Company had total long-term debt of approximately $71 million, with a current portion of $4 million[124] - The applicable interest rate under the Second Amended and Restated Credit Agreement was approximately 4.6% as of September 30, 2022[122] Future Plans and Investments - The Company plans to fund its operating expenses and growth through internally generated cash and bank credit facilities[114] - The Company plans to continue adding capacity to enhance operating efficiencies in its manufacturing plants throughout fiscal 2022[130] - The Company anticipates that future expansion will be financed through existing resources, cash flow from operations, and the revolving credit facility[131] - Approximately $9.4 million was available for future repurchases of the Company's common stock under the stock repurchase program as of September 30, 2022[132] - The Company used cash of approximately $144 thousand for operations during the nine months ended September 30, 2022, and cannot guarantee future cash generation[129] Other Financial Activities - The Company recorded a net gain on the sale of its molded fiber business of approximately $15.6 million, with proceeds used to pay down debt[106]

Welcome Investors September 21, 2022 S TECHNOLOGIES Forward Looking Statements Certain statements in this presentation may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may be identified by words such as "may," "should," "expect," "intend," "will," "estimate," "anticipat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2022 Commission File Number: 001-12648 UFP Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 04-2314970 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( ...

Welcome Investors June 16, 2022 音 UFP TECHNOLOGIES Forward Looking Statements Certain statements in this presentation may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may be identified by words such as "may," "should," "expect," "intend," "will," "estimate," "anticipate ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-12648 UFP Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 04-2314970 (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-12648 UFP Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 04-2314970 (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-12648 UFP Technologies, Inc. (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Iden ...

Welcome Investors September 2021 W UFP TECHNOLOGIES® Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company's prospects, anticipated advantages the Company expects to realize from its acquisition strategies, the Company's financial performance, targets, goals, and metrics, participation in multiple markets, its engineering and product development resources, the benefits of the Company's product development bu ...

Sales Performance - Sales for the three-month period ended June 30, 2021 increased approximately 18.8% to $50.7 million from $42.6 million for the same period in 2020[79] - Sales for the six-month period ended June 30, 2021 increased approximately 9.2% to $99.3 million from $90.9 million for the same period in 2020[80] Gross Margin - Gross margin for the three-month period ended June 30, 2021 increased to 26.5% from 23.3% for the same period in 2020[81] - Gross margin for the six-month period ended June 30, 2021 increased to 26.2% from 25.0% for the same period in 2020[82] Expenses - Selling, general, and administrative expenses (SG&A) increased approximately 8.4% to $7.2 million for the three-month period ended June 30, 2021[83] - SG&A as a percentage of sales decreased to 14.3% for the three-month period ended June 30, 2021, from 15.6% for the same period in 2020[83] Interest and Tax - Net interest income was approximately $21 thousand for the three-month period ended June 30, 2021, compared to net interest expense of approximately $33 thousand for the same period in 2020[85] - The Company recorded tax expense of approximately 24.2% for the three-month period ended June 30, 2021, compared to 20.8% for the same period in 2020[88] - The effective tax rate for the six-month period ended June 30, 2021, was approximately 22.9%, an increase from 18.9% in the same period of 2020[89] Cash Flow - Net cash provided by operations for the six-month period ended June 30, 2021, was approximately $9.9 million, primarily driven by net income of approximately $8.9 million[91] - Net cash used in investing activities during the same period was approximately $3.3 million, mainly for additions of manufacturing machinery and equipment[92] - Net cash used in financing activities was approximately $0.6 million, primarily due to payments for stock options exercised and restricted stock units vested[94] - The Company generated cash of approximately $9.9 million in operations during the six months ended June 30, 2021, but future cash generation cannot be guaranteed[102] Credit and Financing - The Company has an unsecured $70 million Amended and Restated Credit Agreement, with a maturity date extended to December 31, 2025[97] - As of June 30, 2021, the Company had no amounts outstanding under the Restated Credit Agreement, with an applicable interest rate of approximately 1.09%[99] Future Plans and Challenges - The Company plans to continue its strategy of organic growth and growth through strategic acquisitions[71] - The Company expects to face ongoing challenges due to the COVID-19 pandemic, impacting its business and financial results[72] - The Company plans to continue adding capacity to enhance operating efficiencies and may consider additional acquisitions[103] - Approximately $9.4 million remains available for future stock repurchases under the authorized program[105] Market Risks - There have been no material changes in market risks as previously disclosed in the Annual Report for the year ended December 31, 2020[108]